Annexon’s ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
About Annexon Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement ...
Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results